• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    8/28/23 4:15:25 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email
    SC 13D/A 1 tm2324813d2_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Enliven Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    29337E102

    (CUSIP Number)

     

    5AM Venture Management, LLC

    Attn: Rebecca Lucia, Chief Financial Officer

    501 2nd Street, Suite 350

    San Francisco, CA 94107

    (415) 993-8565

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    August 24, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Ventures VI, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    WC

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    4,470,968 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    4,470,968 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,470,968 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    10.9% (3)

    14.

    Type of Reporting Person (See Instructions)

    PN

           
    (1)This Schedule 13D is filed by 5AM Ventures VI, L.P. (“Ventures VI”), 5AM Partners VI, LLC (“Partners VI”), 5AM Opportunities I, L.P. (“Opportunities”), 5AM Opportunities I (GP), LLC (“Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VI, Partners VI, Opportunities, Opportunities GP and Schwab, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based upon 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023.

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Partners VI, LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    4,470,968 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    4,470,968 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,470,968 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    10.9% (3)

    14.

    Type of Reporting Person (See Instructions)

    OO

           
    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based upon 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023.

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Opportunities I, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    WC

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    887,507 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    887,507 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    887,507 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    2.2% (3)

    14.

    Type of Reporting Person (See Instructions)

    PN

           
    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)This percentage is calculated based upon 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023.

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Opportunities I (GP), LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    887,507 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    887,507 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    887,507 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    2.2% (3)

    14.

    Type of Reporting Person (See Instructions)

    OO

           
    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)This percentage is calculated based upon 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023.

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    Kush Parmar

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    5,358,475 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    5,358,475 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,358,475 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    13.0% (3)

    14.

    Type of Reporting Person (See Instructions)

    IN

           
    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes (i) 4,470,968 shares of Common Stock held by Ventures VI and (ii) 887,507 shares of Common Stock held by Opportunities. Partners VI serves as the sole general partner of Ventures VI and Opportunities GP serves as the sole general partner of Opportunities. As managing members of each of Partners VI and Opportunities GP, Schwab and Parmar share voting and dispositive power over the shares held by each of Ventures VI and Opportunities.

     

    (3)This percentage is calculated based upon 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023.

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    Andrew J. Schwab

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x  (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    3,063 shares (2)

    8.

    Shared Voting Power

    5,358,475 shares (3)

    9.

    Sole Dispositive Power

    3,063 shares (2)

    10.

    Shared Dispositive Power

    5,358,475 shares (3)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,361,538 shares (2)(3)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    13.0% (3)

    14.

    Type of Reporting Person (See Instructions)

    IN

           
    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes 3,063 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options held by Schwab.

     

    (3)Includes (i) 4,470,968 shares of Common Stock held by Ventures VI and (ii) 887,507 shares of Common Stock held by Opportunities. Partners VI serves as the sole general partner of Ventures VI and Opportunities GP serves as the sole general partner of Opportunities. As managing members of each of Partners VI and Opportunities GP, Schwab and Parmar share voting and dispositive power over the shares held by each of Ventures VI and Opportunities.

     

    (4)This percentage is calculated based upon the sum of (i) 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023 and (ii) 3,063 shares of Common Stock issuable upon exercise of stock options.

     

     

     

     

    Explanatory Note: This Amendment No. 1 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2023 (the “Original Schedule 13D”) on behalf of 5AM Ventures VI, L.P. (“Ventures VI”), 5AM Partners VI, LLC (“Partners VI”), 5AM Opportunities I, L.P. (“Opportunities”), 5AM Opportunities I (GP), LLC (“Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VI, Partners VI, Opportunities, Opportunities GP and Schwab, collectively, the “Reporting Persons”) relates to the Common Stock, par value $0.001 per share (“Common Stock”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment is being filed by the Reporting Persons to report open market sales of Common Stock on August 24, 2023. Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

     

    Items 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

     

    Item 4.Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

     

    On August 24, 2023, Ventures VI sold an aggregate of 367,124 shares of Common Stock and Opportunities sold an aggregate of 72,876 shares of Common Stock, each in open market transactions at prices ranging from $16.00 to $16.60 per share (a weighted-average price of $16.00 per share).

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of March 6, 2023:

     

    Reporting Persons  Shares
    Held
    Directly
       Sole Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (4)
     
    Ventures VI   4,470,968    0    4,470,968    0    4,470,968    4,470,968    10.9%
    Partners VI (1)   0    0    4,470,968    0    4,470,968    4,470,968    10.9%
    Opportunities   887,507    0    887,507    0    887,507    887,507    2.2%
    Opportunities GP (2)   0    0    887,507    0    887,507    887,507    2.2%
    Schwab (1) (2) (3)   3,063    3,063    5,358,475    3,063    5,358,475    5,361,538    13.0%
    Parmar (1) (2)   0    0    5,358,475    0    5,358,475    5,358,475    13.0%

     

    (1)Includes 4,470,968 shares of Common Stock directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (2)Includes 887,507 shares of Common Stock directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)Includes 3,063 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options.

     

    (4)This percentage is calculated based upon the sum of (i) 41,151,111 shares of Common Stock outstanding as of August 1, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the Securities and Exchange Commission on August 10, 2023 and (ii) shares of Common Stock issuable upon exercise of stock options, as applicable.

     

     

     

     

    (c)Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Not applicable.

     

    Item 7.Material to be Filed as Exhibits

     

    A.Joint Filing Agreement, dated December 13, 2021 (incorporated by reference to the Original Schedule 13D, filed on March 6, 2023).

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 28, 2023

     

    5AM Ventures VI, L.P.  
         
    By: 5AM Partners VI, LLC  
    its General Partner  
         
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
         
    5AM Partners VI, LLC  
         
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
         
    5AM Opportunities I, L.P.  
         
    By: 5AM Opportunities I (GP), LLC  
    its General Partner  
         
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
         
    5AM Opportunities I (GP), LLC  
         
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
         
    /s/ Andrew J. Schwab  
    Andrew J. Schwab  
         
    /s/ Dr. Kush Parmar  
    Dr. Kush Parmar  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $IMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on Imara with a new price target

      Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

      1/6/22 10:34:33 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Imara with a new price target

      HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

      11/30/21 7:23:31 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

      8/11/21 6:17:27 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Imara Announces Stockholder Approval of Merger With Enliven

      -- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

      2/22/23 4:01:00 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lifshitz Law PLLC Announces Investigations of IMRA, AGFS, USER, and PEBO

      NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

      11/23/22 7:48:00 PM ET
      $AGFS
      $IMRA
      $PEBO
      $USER
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Banks
      Finance
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • 5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/16/24 4:15:31 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Phillips Andrew John

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:04:08 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Patel Anish

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:02:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

      SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/16/24 4:15:28 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 8:53:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 4:58:16 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    SEC Filings

    See more
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/15/24 5:04:57 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/20/23 6:06:54 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/19/23 5:27:50 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

      Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

      11/8/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

      BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

      6/30/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

      BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

      1/20/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Reports Full Year 2021 Financial Results and Business Highlights

      Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

      3/15/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

      BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800

      3/8/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care